The estimated Net Worth of Richard J Rubino is at least $13.7 Million dollars as of 9 September 2019. Mr. Rubino owns over 5,040 units of Aerie Pharmaceuticals Inc stock worth over $5,176,552 and over the last 11 years he sold AERI stock worth over $6,088,326. In addition, he makes $2,465,410 as Chief Financial Officer, Treasurer, and Secretary at Aerie Pharmaceuticals Inc.
Richard has made over 5 trades of the Aerie Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 5,040 units of AERI stock worth $100,447 on 9 September 2019.
The largest trade he's ever made was selling 66,605 units of Aerie Pharmaceuticals Inc stock on 26 September 2018 worth over $4,011,619. On average, Richard trades about 5,050 units every 93 days since 2013. As of 9 September 2019 he still owns at least 339,446 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Mr. Rubino stock trades at the bottom of the page.
Richard J. Rubino CPA serves as Chief Financial Officer, Treasurer, Secretary of the Company. From March 2008 to April 2012, Mr. Rubino served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. and from May 1993 to March 2008 served as Controller, Chief Accounting Officer and Vice President of Planning. Previously, Mr. Rubino held various positions at International Business Machines Corporation from 1983 to May 1993 and PricewaterhouseCoopers LLP (formerly Price Waterhouse & Co.) from 1979 to 1983. Mr. Rubino received his B.S. in Accounting from Manhattan College. He has been a director of the Northside Center for Child Development since 2009, the Board Treasurer from 2012 through 2016 and became Board President in 2016. He also currently serves as a member of the Finance Committee and Executive Committee.
As the Chief Financial Officer, Treasurer, and Secretary of Aerie Pharmaceuticals Inc, the total compensation of Richard Rubino at Aerie Pharmaceuticals Inc is $2,465,410. There are 3 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of $5,529,670.
Richard Rubino is 62, he's been the Chief Financial Officer, Treasurer, and Secretary of Aerie Pharmaceuticals Inc since 2015. There are 9 older and 10 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra, and Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: